Rapport Therapeutics (NASDAQ:RAPP) Insider Sells $357,816.00 in Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) insider Krishnaswamy Yeleswaram sold 10,200 shares of the stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $35.08, for a total transaction of $357,816.00. Following the completion of the sale, the insider owned 266,651 shares of the company’s stock, valued at approximately $9,354,117.08. This represents a 3.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Krishnaswamy Yeleswaram also recently made the following trade(s):

• On Monday, April 13th, Krishnaswamy Yeleswaram sold 9,165 shares of Rapport Therapeutics stock. The shares were sold at an average price of $34.97, for a total transaction of $320,500.05.
• On Friday, April 10th, Krishnaswamy Yeleswaram sold 500 shares of Rapport Therapeutics stock. The shares were sold at an average price of $34.98, for a total transaction of $17,490.00.
• On Wednesday, April 8th, Krishnaswamy Yeleswaram sold 360 shares of Rapport Therapeutics stock. The shares were sold at an average price of $34.90, for a total transaction of $12,564.00.

Rapport Therapeutics Stock Up 4.3%

NASDAQ RAPP traded up $1.50 during trading hours on Tuesday, reaching $36.15. 496,199 shares of the company were exchanged, compared to its average volume of 328,964. Rapport Therapeutics, Inc. has a 1 year low of $7.73 and a 1 year high of $42.27. The business’s 50 day simple moving average is $29.41 and its 200-day simple moving average is $28.29. The stock has a market capitalization of $1.73 billion, a P/E ratio of -12.64 and a beta of 1.09.

Rapport Therapeutics (NASDAQ:RAPP) last posted its quarterly earnings data on Tuesday, March 10th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.07). As a group, sell-side analysts anticipate that Rapport Therapeutics, Inc. will post -3.65 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on RAPP shares. Weiss Ratings restated a “sell (d-)” rating on shares of Rapport Therapeutics in a report on Thursday, January 22nd. Citigroup restated a “market outperform” rating on shares of Rapport Therapeutics in a report on Tuesday, March 10th. Wells Fargo & Company raised their price objective on shares of Rapport Therapeutics from $43.00 to $46.00 and gave the stock an “overweight” rating in a report on Wednesday, March 11th. BTIG Research raised their price objective on shares of Rapport Therapeutics to $47.00 and gave the stock a “buy” rating in a report on Monday, March 9th. Finally, TD Cowen restated a “buy” rating on shares of Rapport Therapeutics in a report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Rapport Therapeutics has an average rating of “Buy” and a consensus price target of $53.83.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Capital International Investors boosted its holdings in Rapport Therapeutics by 30.7% in the 3rd quarter. Capital International Investors now owns 3,402,529 shares of the company’s stock worth $101,055,000 after buying an additional 800,000 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Rapport Therapeutics by 23.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 3,001,879 shares of the company’s stock worth $91,077,000 after buying an additional 579,903 shares during the period. Vanguard Group Inc. boosted its holdings in Rapport Therapeutics by 11.8% in the 4th quarter. Vanguard Group Inc. now owns 1,817,757 shares of the company’s stock worth $55,151,000 after buying an additional 191,219 shares during the period. Baker BROS. Advisors LP boosted its holdings in Rapport Therapeutics by 181.2% in the 3rd quarter. Baker BROS. Advisors LP now owns 1,547,090 shares of the company’s stock worth $45,949,000 after buying an additional 997,000 shares during the period. Finally, Alliancebernstein L.P. boosted its holdings in Rapport Therapeutics by 4.1% in the 2nd quarter. Alliancebernstein L.P. now owns 1,154,688 shares of the company’s stock worth $13,129,000 after buying an additional 45,063 shares during the period.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.